Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mFOLFIRINOX + algenpantucel-L
- Development stage
- Discontinued
- Lead developer
- Lumos Pharma
- Modality
- Cell Therapies, Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Intradermal
01
Overview
mFOLFIRINOX + algenpantucel-L is a chemo-immunotherapy combination investigated for the treatment of pancreatic cancer. The regimen consists of a modified FOLFIRINOX chemotherapy backbone (comprising 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) and algenpantucel-L, an allogeneic cancer vaccine. Algenpantucel-L is composed of two irradiated allogeneic pancreatic cancer cell lines (HAPa-1 and HAPa-2) genetically engineered to express alpha-1,3-galactosyl epitopes (alpha-gal). The presence of these epitopes on the vaccine cells triggers a hyperacute rejection-like immune response, stimulating the patient's immune system to recognize and attack endogenous pancreatic cancer cells. The modified FOLFIRINOX component provides a cytotoxic effect by inhibiting DNA synthesis and repair, typically administered with reduced irinotecan doses and the omission of the 5-FU bolus to improve tolerability compared to the original FOLFIRINOX regimen.
- Other names
- modified FOLFIRINOX plus algenpantucel-LmFOLFIRINOX + HAPmFOLFIRINOX + algenpantucel-L
Beyond the preview
Go deeper on mFOLFIRINOX + algenpantucel-L.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mFOLFIRINOX + algenpantucel-L.